• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia.

作者信息

Iurlo Alessandra, Bucelli Cristina, Cattaneo Daniele, Levati Giorgia Virginia, Viani Benedetta, Tavazzi Dario, Consonni Dario, Baldini Luca, Cappellini Maria Domenica

机构信息

Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.

Department of Clinical Sciences and Community Health, University of Milan, and Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

出版信息

Am J Hematol. 2019 Nov;94(11):E283-E285. doi: 10.1002/ajh.25596. Epub 2019 Aug 9.

DOI:10.1002/ajh.25596
PMID:31364196
Abstract
摘要

相似文献

1
UGT1A1 genotype does not affect tyrosine kinase inhibitors efficacy and safety in chronic myeloid leukemia.UGT1A1基因分型不影响酪氨酸激酶抑制剂在慢性髓性白血病中的疗效和安全性。
Am J Hematol. 2019 Nov;94(11):E283-E285. doi: 10.1002/ajh.25596. Epub 2019 Aug 9.
2
Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia.UGT1A1基因6、27和28位点多态性对日本慢性髓性白血病患者尼罗替尼诱导的高胆红素血症的影响。
Drug Metab Pharmacokinet. 2014;29(6):449-54. doi: 10.2133/dmpk.DMPK-14-RG-031. Epub 2014 Jun 3.
3
Nilotinib-induced liver injury: A case report.尼罗替尼所致肝损伤：一例报告。
Medicine (Baltimore). 2020 Sep 4;99(36):e22061. doi: 10.1097/MD.0000000000022061.
4
Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.
Acta Oncol. 2010 Apr;49(3):399-400. doi: 10.3109/02841860903521129.
5
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.尼洛替尼治疗伊马替尼耐药或不耐受的 Ph+ 慢性髓性白血病加速期患者：24 个月随访结果。
Leukemia. 2012 Jun;26(6):1189-94. doi: 10.1038/leu.2011.323. Epub 2011 Nov 11.
6
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.达沙替尼与伊马替尼治疗日本新诊断慢性期慢性髓性白血病（CML-CP）患者的疗效与安全性：DASISION试验2年随访的亚组分析
Int J Hematol. 2014 Feb;99(2):141-53. doi: 10.1007/s12185-013-1470-1. Epub 2013 Dec 20.
7
Comment on "efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors".关于“达沙替尼在对BCR-ABL1酪氨酸激酶抑制剂耐药或不耐受的慢性期慢性髓性白血病患者中的疗效和安全性”的评论
Haematologica. 2015 Mar;100(3):e120-1. doi: 10.3324/haematol.2014.123232.
8
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.帕唑帕尼引起的高胆红素血症与吉尔伯特综合征 UGT1A1 多态性相关。
Br J Cancer. 2010 Apr 27;102(9):1371-7. doi: 10.1038/sj.bjc.6605653. Epub 2010 Apr 13.
9
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.伊马替尼治疗失败的老年慢性期慢性髓性白血病患者中 BCR-ABL 突变对达沙替尼反应的影响。
Ann Hematol. 2013 Jan;92(2):179-83. doi: 10.1007/s00277-012-1591-2. Epub 2012 Oct 10.
10
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.达沙替尼 100mg 与伊马替尼 400mg 治疗初诊慢性期慢性髓性白血病的随机试验。
Blood. 2012 Nov 8;120(19):3898-905. doi: 10.1182/blood-2012-02-410688. Epub 2012 Aug 22.

引用本文的文献

1
Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation.引导式癌症治疗：临床实施的证据综述与考量
Cancers (Basel). 2021 Mar 29;13(7):1566. doi: 10.3390/cancers13071566.